Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer-Reference-Cited by-同舟云学术

Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer

Published:2015-09-09 Issue:5 Volume:23 Page:771-779
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Noguchi Shinzaburo,Kim Hee Jeong,Jesena Anita,Parmar Vani,Sato Nobuaki,Wang Hwei-Chung,Lokejaroenlarb Santi,Isidro Jofel,Kim Ku Sang,Itoh Yohji,Shin Eisei

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-015-0637-4.pdf

Reference19 articles.

1. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21:28–34.

2. Hilakivi-Clarke L, Cabanes A, Olivo S, Kerr L, Bouker KB, Clarke R. Do estrogens always increase breast cancer risk? J Steroid Biochem Mol Biol. 2002;80:163–74.

3. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, De Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20:4628–35.